|
1
|
Siegel RL, Miller KD, Goding SA, Fedewa
SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal A:
Colorectal cancer statistics, 2020. CA Cancer J Clin. 70:145–164.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Custodio A and Feliu J: Prognostic and
predictive biomarkers for epidermal growth factor receptor-targeted
therapy in colorectal cancer: Beyond KRAS mutations. Crit Rev Oncol
Hematol. 85:45–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lim KH, Song MH and Baek KH: Decision for
cell fate: Deubiquitinating enzymes in cell cycle checkpoint. Cell
Mol Life Sci. 73:1439–1455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou MJ, Chen FZ and Chen HC:
Ubiquitination involved enzymes and cancer. Med Oncol. 31:932014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rickman KA, Lach FP, Abhyankar A, Donovan
FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O,
Chandrasekharappa SC, et al: Deficiency of UBE2T, the E2 ubiquitin
ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T
subtype of fanconi anemia. Cell Rep. 12:35–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alpi A, Langevin F, Mosedale G, Machida
YJ, Dutta A and Patel KJ: UBE2T, the Fanconi anemia core complex,
and FANCD2 are recruited independently to chromatin: A basis for
the regulation of FANCD2 monoubiquitination. Mol Cell Biol.
27:8421–8430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joenje H and Patel KJ: The emerging
genetic and molecular basis of Fanconi anaemia. Nat Rev Genet.
2:446–457. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weiser MR: AJCC 8th edition: Colorectal
cancer. Ann Surg Oncol. 25:1454–1455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee YT, Tan YJ and Oon CE: Molecular
targeted therapy: Treating cancer with specificity. Eur J
Pharmacol. 834:188–196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nikolaou S, Qiu S, Fiorentino F, Rasheed
S, Tekkis P and Kontovounisios C: Systematic review of blood
diagnostic markers in colorectal cancer. Tech Coloproctol.
22:481–498. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhatti I, Patel M, Dennison AR, Thomas MW
and Garcea G: Utility of postoperative CEA for surveillance of
recurrence after resection of primary colorectal cancer. Int J
Surg. 16:123–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsilimigras DI, Ntanasis-Stathopoulos I,
Bagante F, Moris D, Cloyd J, Spartalis E and Pawlik TM: Clinical
significance and prognostic relevance of KRAS, BRAF, PI3K and TP53
genetic mutation analysis for resectable and unresectable
colorectal liver metastases: A systematic review of the current
evidence. Surg Oncol. 27:280–288. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raskov H, Pommergaard HC, Burcharth J and
Rosenberg J: Colorectal carcinogenesis-update and perspectives.
World J Gastroenterol. 20:18151–18164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bassermann F, Eichner R and Pagano M: The
ubiquitin proteasome system-implications for cell cycle control and
the targeted treatment of cancer. Biochim Biophys Acta.
1843:150–162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Teixeira LK and Reed SI: Ubiquitin ligases
and cell cycle control. Annu Rev Biochem. 82:387–414. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alpi AF, Chaugule V and Walden H:
Mechanism and disease association of E2-conjugating enzymes:
Lessons from UBE2T and UBE2L3. Biochem J. 473:3401–3419. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hira A, Yoshida K, Sato K, Okuno Y,
Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shimamoto A, Tahara H, et
al: Mutations in the gene encoding the E2 conjugating enzyme UBE2T
cause Fanconi anemia. Am J Hum Genet. 96:1001–1007. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Longerich S, San Filippo J, Liu D and Sung
P: FANCI binds branched DNA and is monoubiquitinated by
UBE2T-FANCL. J Biol Chem. 284:23182–23186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelsall IR, Langenick J, MacKay C, Patel
KJ and Alpi AF: The Fanconi anaemia components UBE2T and FANCM are
functionally linked to nucleotide excision repair. PLoS One.
7:e369702012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ueki T, Park JH, Nishidate T, Kijima K,
Hirata K, Nakamura Y and Katagiri T: Ubiquitination and
downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T
overexpression in human breast cancer cells. Cancer Res.
69:8752–8760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gong YQ, Peng D, Ning XH, Yang XY, Li XS,
Zhou LQ and Guo YL: UBE2T silencing suppresses proliferation and
induces cell cycle arrest and apoptosis in bladder cancer cells.
Oncol Lett. 12:4485–4492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hao J, Xu A, Xie X, Hao J, Tian T, Gao S,
Xiao X and He D: Elevated expression of UBE2T in lung cancer tumors
and cell lines. Tumour Biol. 29:195–203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu H, Xiang P, Pan Q, Huang Y, Xie N and
Zhu W: Ubiquitin-conjugating enzyme E2T is an independent
prognostic factor and promotes gastric cancer progression. Tumour
Biol. 37:11723–11732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu W, Xiao L, Cao C, Hua S and Wu D: UBE2T
promotes nasopharyngeal carcinoma cell proliferation, invasion, and
metastasis by activating the AKT/GSK3β/β-catenin pathway.
Oncotarget. 7:15161–15172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu M, Li X, Huang W, Chen Y, Wang B and
Liu X: Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal
cancer progression by facilitating ubiquitination and degradation
of p53. Clin Res Hepatol Gastroenterol. Jul 29–2020.(Online ahead
of print). View Article : Google Scholar
|
|
29
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sica V, Bravo-San Pedro JM, Stoll G and
Kroemer G: Oxidative phosphorylation as a potential therapeutic
target for cancer therapy. Int J Cancer. 146:10–17. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Slattery ML, Mullany LE, Wolff RK, Sakoda
LC, Samowitz WS and Herrick JS: The p53-signaling pathway and
colorectal cancer: Interactions between downstream p53 target genes
and miRNAs. Genomics. 111:762–771. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bashir T and Pagano M: Aberrant
ubiquitin-mediated proteolysis of cell cycle regulatory proteins
and oncogenesis. Adv Cancer Res. 88:101–144. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Patra KC and Hay N: The pentose phosphate
pathway and cancer. Trends Biochem Sci. 39:347–354. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mamrak NE, Shimamura A and Howlett NG:
Recent discoveries in the molecular pathogenesis of the inherited
bone marrow failure syndrome Fanconi anemia. Blood Rev. 31:93–99.
2017. View Article : Google Scholar : PubMed/NCBI
|
